Today: 7 February 2026
Subscribe
Browse Category

NYSE:TOST News 19 December 2025

Toast (TOST) Stock News on Dec. 19, 2025: Analyst Targets Reset, 2026 Outlook Signals, and What Investors Are Watching

Toast (TOST) Stock News on Dec. 19, 2025: Analyst Targets Reset, 2026 Outlook Signals, and What Investors Are Watching

Toast, Inc. (NYSE: TOST) stock is ending 2025 with the kind of “quietly dramatic” setup markets love: a fast-growing restaurant-tech platform, improving profitability, and a fresh wave of analyst notes that trim price targets while keeping bullish ratings intact. In the latest available quote, Toast shares were around $36.62, up about 3% from the prior close. Investing.com So what’s driving the conversation around Toast stock on 19.12.2025? Three threads stand out: Toast stock price action: where TOST stands heading into the Dec. 19 news cycle On the most recent completed session shown in Investing.com’s daily history, Toast closed Dec. 18,
19 December 2025
·

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop